Market news

Detailed price information for Universal Health Services (UHS-N) from The Globe and Mail including charting and trades.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

A caller asked for Jim Cramer’s long-term thoughts on Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) during the lightning round of the September 14 episode of Mad Money. He replied: They have a good model. They remind me of Hinge, not exactly, but in just this kind of discreet good model will make money. And I think […]

Does Aveanna Healthcare (AVAH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Aveanna (AVAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Why Aveanna Healthcare Holdings (AVAH) Is On Value Investors’ Radar Recent research flagged Aveanna Healthcare Holdings (AVAH) as potentially undervalued, with valuation ratios that compare favorably with industry peers and an earnings outlook that has attracted fresh attention from value focused investors. This combination of relatively lower P/E, P/S, and P/CF metrics, together with that earnings view, has turned a spotlight on how the market is currently pricing Aveanna Healthcare and what...

The updated analyst work on Aveanna Healthcare Holdings centers on a higher fair value estimate, moving from US$9.95 to US$13.90. This points to a meaningfully higher price target range in the low to mid teens. Analysts tie this shift to the Q2 report, the refreshed long term framework through 2027, and to how reimbursement trends and state rate decisions could influence the stock over time. Read on to see what is driving the evolving story around Aveanna Healthcare Holdings and how you can...

Outpatient and home healthcare stocks gain from aging, digital care and AI, with LifeStance, Option Care, Aveanna and DaVita in focus.

Detailed price information for Aveanna Healthcare Holdings Inc (AVAH-Q) from The Globe and Mail including charting and trades.

Aveanna Healthcare (AVAH) exhibits strong technical momentum, with a more-than-70% gain over the past year. Shares are trading at a new all-time high. Multiple analysts rate AVAH a “Strong Buy,” supported by robust growth, profitability, and valuation metrics. Technical indicators remain bullish: RSI above 70, 11 new highs in the...

Aveanna (AVAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Does Aveanna Healthcare (AVAH) have what it takes to be a top stock pick for momentum investors? Let's find out.

ATLANTA, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the Deutsche Bank 2026 Healthcare Summit in New York on September 16, 2026. Management will host a fireside chat at 1:00pm EST along with 1x1 investor meetings that same day. Interested investors and other parties may also listen to a simultaneous webcast of the presentation by logging onto the Investor Relations section of the Company’s webs

Aveanna Healthcare (AVAH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Detailed price information for Enovis Corp (ENOV-N) from The Globe and Mail including charting and trades.

On August 13, Aveanna Healthcare (NASDAQ:AVAH) held its second-quarter earnings call, and the tone was different from prior quarters spent explaining away a caregiver shortage. Revenue climbed 13.7% year over year to roughly $670 million, and every one of the company’s three divisions grew. But the headline moment came when CEO Jeffrey Shaner announced that […]

Aveanna Healthcare Holdings has delivered a very large 3 year return, yet the valuation checks still suggest the stock leans cheap overall. With sentiment shaped by both a strong share price run and fresh news around a secondary offering and higher long term growth ambitions, investors are asking whether the current price still reflects a discount. Aveanna Healthcare Holdings has returned about 8x over the last 3 years, which puts extra focus on whether that pace is now fully reflected in...

ATLANTA, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, announced today that certain...

Detailed price information for Aveanna Healthcare Holdings Inc (AVAH-Q) from The Globe and Mail including charting and trades.

Aveanna raises its 2026 outlook and long-term growth targets as reimbursement gains and preferred payers support expansion.

Aveanna Healthcare (AVAH) stock hits a 52-week high after the company reported better-than-expected Q2 2026 financials and raised its full-year outlook. Read more here.

Aveanna Healthcare Holdings Inc (AVAH) reports a 13.7% revenue increase and raises full-year 2026 outlook, driven by robust segment performance and strategic payer agreements.

Moby summary of Aveanna Healthcare Holdings Inc.'s Q2 2026 earnings call

Aveanna Healthcare (NASDAQ:AVAH) reported higher second-quarter revenue and adjusted EBITDA, supported by growth across its three operating divisions, improved reimbursement rates, increased volumes and operational efficiencies. The company also raised its full-year outlook and updated its long-term

Although the revenue and EPS for Aveanna (AVAH) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Aveanna (AVAH) delivered earnings and revenue surprises of +29.41% and +3.62%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Second Quarter Revenue was $670.5 million, a 13.7% increase over the prior year periodSecond Quarter Net income was $40.3 million compared to $27.0 million for the prior year periodAdjusted EBITDA for Q2 2026 was $95.4 million, an 8.0% increase over the prior year periodIncreased Full Year 2026 Revenue guidance to greater than $2.68 billion, updated from between $2.63 and $2.65 billion Increased Full Year 2026 Adjusted EBITDA guidance to greater than $365 million, updated from between $338 and $